NCT03600441 2025-04-10
FORERUNNER
Xynomic Pharmaceuticals, Inc.
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03934567 2025-04-10
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT03936153 2025-04-10
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2 Recruiting